To cure Angelman syndrome by accelerating translational research, building clinical infrastructure, and advocating for patients and families.
Foundation for Angelman Syndrome Therapeutics centers its giving on one disease area: translational work aimed at curing Angelman syndrome. The largest recent commitment in the record is a $5,860,869 grant to the University of Pennsylvania for a research, collaboration, and license agreement, underscoring how heavily the foundation uses long-horizon research partnerships to move therapeutic candidates forward. Its portfolio also includes a $1,287,600 grant to Rush University Medical Center and repeated support for cross-institution projects that link preclinical development with clinical readiness. The foundation funds a broad technical mix within Angelman syndrome research, including gene therapy, antisense oligonucleotides, CRISPR and gene editing, biomarkers, clinical trial readiness, patient registries, and newborn screening. That scope is reflected in grants to Boston Children’s Hospital for a natural history study, and to the University of California, San Francisco for development of a CRISPR therapy for the Class I/II deletion genotype. The foundation is organized as a public charity and also makes program-related investments, which fits a strategy that extends beyond standard grants into research acceleration and infrastructure support.
A major theme is model and platform development for translational research. The foundation supported Yale University with $257,475 for generation and characterization of a new Angelman syndrome mouse model, and North Carolina State University with $178,887 for microprobe-integrated human organoid arrays to study genotypes and therapeutics. Biomarker work is another clear area: Children’s Research Institute received $246,600 for peak alpha frequency as an EEG biomarker for Angelman syndrome, while the University of California, Davis received $274,044 for gastrointestinal biomarkers in preclinical models. The foundation also funds therapeutic engineering, including $250,000 to Keck Graduate Institute of Applied Life Sciences to target therapeutics to the brain using novel cell-penetrating peptides. Workforce development appears in its postdoctoral fellowship grants, such as $50,500 to Brown University for a postdoctoral fellowship program.
$7.9M
$44.9M
$5.4M
$10.4M
Most grants fall between $75K and $257K, with a median of $179K.
25th Percentile
$75K
Median
$179K
75th Percentile
$257K
About 7% of grants go to recipients in NC.
Sign up for a free Kindora account to access AI-generated insights into this funder's giving patterns, decision-makers, and fit signals.
Get Started FreeFree Kindora accounts unlock side-by-side comparisons with foundations that share this funder's focus areas and giving profile.
Get Started FreeSign up free to see how well your nonprofit fits this funder, get an AI-generated pitch, and unlock similar foundations.
Recent grants cluster in a mid-to-large range: p25 is $75,445, the median is $178,887, and p75 is $257,475. The pattern is not purely one-off; several recipients appear in multiple years, including the University of Pennsylvania, Boston Children’s Hospital, Yale University, Brown University, Duke University, North Carolina State University, and the University of California, San Francisco. The foundation is a public charity and makes program-related investments, which suggests it can use both grants and investment-style support to advance therapeutic development. Multiple active programs accept unsolicited applications, including New Investigator Award, FAST IMPACT Award, FAST Postdoctoral Fellowship, FAST-TRAC Award, Innovation Seed Grant, and General FAST Research Grants.
Giving is national, with all recent grants in the United States. Washington, DC is the top state by grant count, and recipients there include Children’s Research Institute. The recent record also shows repeated funding in Philadelphia, Chicago, Boston, New Haven, Raleigh, Providence, and San Francisco. Texas recipients account for 10% of grants, with Texas A&M University appearing in College Station. The geographic pattern reflects a U.S.-wide research network rather than a single-region focus.
The foundation funds Angelman syndrome translational and clinical research, including gene therapy, antisense oligonucleotides, CRISPR and gene editing, biomarkers, outcome measures, patient registries, newborn screening, and clinical trial readiness. Its active programs also support preclinical-to-IND-enabling projects and early-stage proof-of-concept work.
Yes. Several active programs accept unsolicited applications, including the New Investigator Award, FAST IMPACT Award, FAST Postdoctoral Fellowship, FAST-TRAC Award, Innovation Seed Grant, FAST Research Grants, and General FAST Research Grants. The collaborative research and development agreement with the University of Pennsylvania is listed as not accepting unsolicited applications.
Typical recent grants cluster around a median of $178,887, with the 25th percentile at $75,445 and the 75th percentile at $257,475. The foundation also makes larger commitments, including a $5,860,869 grant to the University of Pennsylvania.
By count, Washington, DC is the top state for recipient organizations in the recent grants list. Recent DC recipients include Children’s Research Institute, and the broader record includes repeated grants to institutions in Philadelphia, Chicago, Boston, New Haven, Raleigh, Providence, and San Francisco.
Yes. Its New Investigator Award is aimed at early-career researchers within their first five years of an academic position, and the FAST Postdoctoral Fellowship supports postdoctoral researchers working on Angelman syndrome translational projects.
2025
Source: IRS Form 990-PF, fiscal year 2025.
Most recent grants reported to the IRS.
| Recipient | Location | Amount | Year | Purpose |
|---|---|---|---|---|
| UNIVERSITY OF PENNSYLVANIA | PHILADELPHIA, PA | $5,860,869 | 2025 | UPENN 2023: RESEARCH, COLLABORATION & LICENSE AGREEMENT |
| BOSTON CHILDREN'S HOSPITAL | BOSTON, MA | $470,957 | 2025 | FT2022-006: ABOM - NATURAL HISTORY STUDY |
| RUSH UNIVERSITY MEDICAL CENTER | CHICAGO, IL | $320,500 | 2025 | RUSH COE |
| DUKE UNIVERSITY | CHARLOTTE, NC | $317,848 | 2025 | FT2018-005 AMENDED: GPIC-COMM |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA DAVIS | DAVIS, CA | $274,044 | 2025 | FT2022-007: GASTROINTESTINAL BIOMARKERS IN PRECLINICAL MODELS OF ANGELMAN SYNDROME |
| THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO | SAN FRANCISCO, CA | $210,711 | 2025 | FT2023-002: DEVELOPING A CRISPRA THERAPY FOR THE CLASSI/II DELETION GENOTYPE OF ANGELMAN SYNDROME |
| BROWN UNIVERSITY | PROVIDENCE, RI | $150,000 | 2025 | FT2022-005: DEVELOPMENT OF BDNF POTENTIATING THERAPEUTICS FOR MOTOR AND COGNITIVE DYSFUNCTION IN AS |
| CHILDREN'S RESEARCH INSTITUTE | WASHINGTON, DC | $140,846 | 2025 | FT2022-003: PEAK ALPHA FREQUENCY AS AN EEG BIOMARKER FOR ANGELMAN SYNDROME |
| KECK GRADUATE INSTITUTE OF APPLIED LIFE SCIENCES | CLAREMONT, CA | $125,000 | 2025 | FT2022-002: TARGETING ANGELMAN SYNDROME THERAPEUTICS TO THE BRAIN UTILIZING NOVEL CELL PENETRATING PEPTIDES |
| BROWN UNIVERSITY | PROVIDENCE, RI | $50,500 | 2025 | PD2023-001: POSTDOCTORAL FELLOWSHIP PROGRAM |
| UNIVERSITY OF PENNSYLVANIA | PHILADELPHIA, PA | $1,853,255 | 2024 | UPENN 2023: RESEARCH, COLLABORATION & LICENSE AGREEMENT |
| RUSH UNIVERSITY MEDICAL CENTER | CHICAGO, IL | $1,287,600 | 2024 | RUSH COE |
| BOSTON CHILDREN'S HOSPITAL | BOSTON, MA | $458,118 | 2024 | FT2022-006: ABOM - NATURAL HISTORY STUDY |
| TEXAS A&M UNIVERSITY | COLLEGE STATION, TX | $267,142 | 2024 | FT2019-008: TRANSLATIONAL RESEARCH IN PIG MODEL OF AS |
| YALE UNIVERSITY | NEW HAVEN, CT | $257,475 | 2024 | FT2020-006: GENERATION AND CHARACTERIZATION OF A NEW AS MOUSE MODEL THAT RECAPITULATES THE LARGE DELETION OF HUMAN 15Q11-Q13 AND A CONTROL LINE THAT CARRIES A DELETION OF ALL GENES IN 15Q11-Q13 BUT UBE3A |
| KECK GRADUATE INSTITUTE OF APPLIED LIFE SCIENCES | CLAREMONT, CA | $250,000 | 2024 | FT2022-002: TARGETING ANGELMAN SYNDROME THERAPEUTICS TO THE BRAIN UTILIZING NOVEL CELL PENETRATING PEPTIDES |
| CHILDREN'S RESEARCH INSTITUTE | WASHINGTON, DC | $246,600 | 2024 | FT2022-003: PEAK ALPHA FREQUENCY AS AN EEG BIOMARKER FOR ANGELMAN SYNDROME |
| BROWN UNIVERSITY | PROVIDENCE, RI | $194,000 | 2024 | FT2022-005: DEVELOPMENT OF BDNF POTENTIATING THERAPEUTICS FOR MOTOR AND COGNITIVE DYSFUNCTION IN AS |
| NORTH CAROLINA STATE UNIVERSITY | RALEIGH, NC | $178,887 | 2024 | FT2022-001: MICROPROBE-INTEGRATED HUMAN ORGANOID ARRAYS TO STUDY AS GENOTYPES AND THERAPEUTICS |
| NORTH CAROLINA STATE UNIVERSITY | RALEIGH, NC | $161,647 | 2024 | FT2021-002: ISOGENICALLY CONTROLLED HUMAN CELL LINES TARGETING ABERRANT IMPRINTING GENOTYPES AND A NEW REPORTER CELL LINE. |
| THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO | SAN FRANCISCO, CA | $93,702 | 2024 | FT2023-002: DEVELOPING A CRISPRA THERAPY FOR THE CLASSI/II DELETION GENOTYPE OF ANGELMAN SYNDROME |
| DUKE UNIVERSITY | CHARLOTTE, NC | $75,445 | 2024 | FT2018-005 AMENDED: GPIC-COMM |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA DAVIS | DAVIS, CA | $75,000 | 2024 | FT2022-007: GASTROINTESTINAL BIOMARKERS IN PRECLINICAL MODELS OF ANGELMAN SYNDROME |
| BROWN UNIVERSITY | PROVIDENCE, RI | $50,500 | 2024 | PD2023-001: POSTDOCTORAL FELLOWSHIP PROGRAM |
| YALE UNIVERSITY | NEW HAVEN, CT | $50,500 | 2024 | PD2022-001: POSTDOCTORAL FELLOWSHIP PROGRAM |
| NORTH CAROLINA STATE UNIVERSITY | RALEIGH, NC | $43,087 | 2024 | FT2022-008: STEM CELL LINE IN-VITRO INFRASTRUCTURE CREATED AT NCSU FOR INDUSTRY AND ACADEMIC SUPPORT |
| NORTH CAROLINA STATE UNIVERSITY | RALEIGH, NC | $29,315 | 2024 | RADAR 2023-2137 |
| TEXAS A&M UNIVERSITY | COLLEGE STATION, TX | $277,778 | 2023 | TRANSLATIONAL RESEARCH IN PIG MODEL OF AS |
| YALE UNIVERSITY | NEW HAVEN, CT | $233,299 | 2023 | GENERATION AND CHARACTERIZATION OF A NEW AS MOUSE MODEL THAT RECAPITULATES THE LARGE DELETION OF HUMAN 15Q11-Q13 AND A CONTROL LINE THAT CARRIES A DELETION OF ALL GENES IN 15Q11-Q13 BUT UBE3A |
| NORTH CAROLINA STATE UNIVERSITY | RALEIGH, NC | $173,873 | 2023 | BANDODKAR LAB HUMAN ORGANOID ARRAYS TO STUDY AS |
| UNIVERSITY OF PENNSYLVANIA | PHILADELPHIA, PA | $115,121 | 2023 | A. THE UBE3A ANTISENSE TRANSCRIPT (UBE3A-AS) IS A LONG NON-CODING MRNA THAT SILENCES EXPRESSION OF THE PATERNAL UBE3A GENE IN NEURONS. INTERRUPTION OF THIS IMPRINTING PHENOMENON CAN BE DONE THROUGH ASOS, CRISPR-GRNA OR OTHER TECHNOLOGIES LIKE MICRORNA (MIRNA). THIS PROJECT IS AIMING TO DEVELOP A STRATEGY TO SUPPRESS THE UBE3A-AS IN THE MOUSE MODEL OF AS USING MIRNAS. ADVANTAGES TO MIRNA ARE THAT THEY ARE SUBJECT TO ENDOGENOUS CELLULAR PROCESSING AND REGULATION, WHICH CAN HELP CIRCUMVENT ISSUES RELATED TO OVEREXPRESSION OF EXOGENOUS GENETIC MATERIAL (WITH UBE3A REPLACEMENT), AND THE NEED FOR REPEATED REDOSING (WITH ASOS). MIRNA IS THOUGHT TO BE ADVANTAGEOUS OVER SHRNA DUE TO ENDOGENOUS CELLULAR PROCESSING AND REGULATION COMPARED TO OVEREXPRESSION YOU COULD GET WITH SHRNA. |
UPENN 2023: RESEARCH, COLLABORATION & LICENSE AGREEMENT
REGENTS OF THE UNIVERSITY OF CALIFORNIA DAVIS
$274,044FT2022-007: GASTROINTESTINAL BIOMARKERS IN PRECLINICAL MODELS OF ANGELMAN SYNDROME
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO
$210,711FT2023-002: DEVELOPING A CRISPRA THERAPY FOR THE CLASSI/II DELETION GENOTYPE OF ANGELMAN SYNDROME
FT2022-005: DEVELOPMENT OF BDNF POTENTIATING THERAPEUTICS FOR MOTOR AND COGNITIVE DYSFUNCTION IN AS
FT2022-003: PEAK ALPHA FREQUENCY AS AN EEG BIOMARKER FOR ANGELMAN SYNDROME
FT2022-002: TARGETING ANGELMAN SYNDROME THERAPEUTICS TO THE BRAIN UTILIZING NOVEL CELL PENETRATING PEPTIDES
UPENN 2023: RESEARCH, COLLABORATION & LICENSE AGREEMENT
TEXAS A&M UNIVERSITY
$267,142FT2019-008: TRANSLATIONAL RESEARCH IN PIG MODEL OF AS
FT2020-006: GENERATION AND CHARACTERIZATION OF A NEW AS MOUSE MODEL THAT RECAPITULATES THE LARGE DELETION OF HUMAN 15Q11-Q13 AND A CONTROL LINE THAT CARRIES A DELETION OF ALL GENES IN 15Q11-Q13 BUT UBE3A
FT2022-002: TARGETING ANGELMAN SYNDROME THERAPEUTICS TO THE BRAIN UTILIZING NOVEL CELL PENETRATING PEPTIDES
FT2022-003: PEAK ALPHA FREQUENCY AS AN EEG BIOMARKER FOR ANGELMAN SYNDROME
FT2022-005: DEVELOPMENT OF BDNF POTENTIATING THERAPEUTICS FOR MOTOR AND COGNITIVE DYSFUNCTION IN AS
NORTH CAROLINA STATE UNIVERSITY
$178,887FT2022-001: MICROPROBE-INTEGRATED HUMAN ORGANOID ARRAYS TO STUDY AS GENOTYPES AND THERAPEUTICS
NORTH CAROLINA STATE UNIVERSITY
$161,647FT2021-002: ISOGENICALLY CONTROLLED HUMAN CELL LINES TARGETING ABERRANT IMPRINTING GENOTYPES AND A NEW REPORTER CELL LINE.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO
$93,702FT2023-002: DEVELOPING A CRISPRA THERAPY FOR THE CLASSI/II DELETION GENOTYPE OF ANGELMAN SYNDROME
REGENTS OF THE UNIVERSITY OF CALIFORNIA DAVIS
$75,000FT2022-007: GASTROINTESTINAL BIOMARKERS IN PRECLINICAL MODELS OF ANGELMAN SYNDROME
NORTH CAROLINA STATE UNIVERSITY
$43,087FT2022-008: STEM CELL LINE IN-VITRO INFRASTRUCTURE CREATED AT NCSU FOR INDUSTRY AND ACADEMIC SUPPORT
NORTH CAROLINA STATE UNIVERSITY
$29,315RADAR 2023-2137
TEXAS A&M UNIVERSITY
$277,778TRANSLATIONAL RESEARCH IN PIG MODEL OF AS
GENERATION AND CHARACTERIZATION OF A NEW AS MOUSE MODEL THAT RECAPITULATES THE LARGE DELETION OF HUMAN 15Q11-Q13 AND A CONTROL LINE THAT CARRIES A DELETION OF ALL GENES IN 15Q11-Q13 BUT UBE3A
NORTH CAROLINA STATE UNIVERSITY
$173,873BANDODKAR LAB HUMAN ORGANOID ARRAYS TO STUDY AS
A. THE UBE3A ANTISENSE TRANSCRIPT (UBE3A-AS) IS A LONG NON-CODING MRNA THAT SILENCES EXPRESSION OF THE PATERNAL UBE3A GENE IN NEURONS. INTERRUPTION OF THIS IMPRINTING PHENOMENON CAN BE DONE THROUGH ASOS, CRISPR-GRNA OR OTHER TECHNOLOGIES LIKE MICRORNA (MIRNA). THIS PROJECT IS AIMING TO DEVELOP A STRATEGY TO SUPPRESS THE UBE3A-AS IN THE MOUSE MODEL OF AS USING MIRNAS. ADVANTAGES TO MIRNA ARE THAT THEY ARE SUBJECT TO ENDOGENOUS CELLULAR PROCESSING AND REGULATION, WHICH CAN HELP CIRCUMVENT ISSUES RELATED TO OVEREXPRESSION OF EXOGENOUS GENETIC MATERIAL (WITH UBE3A REPLACEMENT), AND THE NEED FOR REPEATED REDOSING (WITH ASOS). MIRNA IS THOUGHT TO BE ADVANTAGEOUS OVER SHRNA DUE TO ENDOGENOUS CELLULAR PROCESSING AND REGULATION COMPARED TO OVEREXPRESSION YOU COULD GET WITH SHRNA.
Current and upcoming funding from Foundation for Angelman Syndrome Therapeutics that your nonprofit may be able to apply for.
Who can apply: Institutions must be recognized nonprofit organizations. Individuals should have training and experience at least equal to the PhD or MD level and pursue research and academic requirements full time or according to institutional policy.
Deadline: Applications are accepted on a rolling basis with no fixed deadline.
Who can apply: Institutions receiving grants must generally be recognized nonprofits. In rare circumstances, contract research organizations or industry scientific teams may receive funding. Individuals should have training and experience at least equal to the PhD or MD level.
Deadline: Applications are accepted on a rolling basis; there is no fixed deadline.
Who can apply: Institutions receiving grants must generally be recognized nonprofits. In rare circumstances, contract research organizations or industry scientific teams may receive funding. Individuals should have training and experience at least equal to the PhD or MD level. Proposed work must be completed within one year. No more than 20% of requested funds may be used for salary and fringe benefits; indirect costs, general office supplies or equipment, and bridging funds are not allowable.
Deadline: All grant applications have a rolling deadline.
Who can apply: Institutions receiving grants are generally recognized as nonprofit organizations. In rare circumstances funding is given to contract research organizations or industry scientific teams. Individuals should have training and experience at least equal to the PhD or MD level.
Deadline: All grant applications have a rolling deadline.
Track these deadlines, get reminders, and see how well your nonprofit fits — free with a Kindora account.
Create a free accountDeadlines and eligibility are summarized from public sources and may change — always confirm the details on the funder's official application page before applying.